Boehringer's survodutide showed 19% GI discontinuation rates in a Phase 3 obesity trial but was on par with Wegovy on weight loss.
Boehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study.
In April …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Weight loss drug maker sinks 25% after new safety data spooks investors
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim, studio di fase III su Survodutide mostra una riduzione mirata del grasso viscerale ed epatico - Il Quotidiano del Sud
Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD
ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
Weekly survodutide confers dual benefits for obesity, metabolic liver disease
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
Monthly GLP-1 for Obesity Promising as More Manageable Alternative
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and…
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
Pfizer's monthly obesity shot, berobenatide, shows similar side effects to Wegovy, aiming for differentiation in the weight-loss…
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new…
6 minuti per la lettura ROMA (ITALPRESS) – Boehringer Ingelheim ha annunciato oggi risultati positivi provenienti da due studi…
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection…
